Treatment of Lung Adenocarcinoma by Liposomal Cisplati
Phase 3
Completed
- Conditions
- Inoperable lung cancerCancer - Lung - Non small cell
- Registration Number
- ACTRN12610000046000
- Lead Sponsor
- George P. Stathopoulos
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Histologically or cytologically confirmed Non-Small-Cell lung cancer, treatment naive, bidimentionally measurable disease , performance status 0-2, expected survival = 12 weeks.
Exclusion Criteria
Second primary malignancy, central nervous system metastasis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate. Assessed mainly by computerized tomography chest x-ray and occasionally magnetic reasonance tomography.[2 years. The 2 years duration was the time period for patients recruitement and 6 months follow-up after the last patient's recruitement (post-treatment).]
- Secondary Outcome Measures
Name Time Method Progression Free Survival (Pfs) and survival. The time from treatment start until the date of disease progression. It was mainly assessed by computerized tomography and also chest x-ray and clinical evaluation. Survival was assessed from treatment start to death or to the time study was closed.[2 years. The 2 years duration was the time period for patients recruitement and 6 months follow-up after the last patient's recruitement (post-treatment).]